Pretax income is the income that a company earns before paying income taxes. Opus Genetics's pretax income for the
three
months ended in Sep. 2024 was $-7.53 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-27.19 Mil.
Opus Genetics's pretax margin was -194.62%.
During the past 5 years, Opus Genetics's highest Pretax Margin was 45.68%. The lowest was -9625.30%. And the median was -52.36%.
Opus Genetics Pre-Tax Income Historical Data
The historical data trend for Opus Genetics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Opus Genetics's Pre-Tax Income
For the Biotechnology subindustry, Opus Genetics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Opus Genetics's Pre-Tax Income falls into.
Opus Genetics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Opus Genetics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (NAS:IRD) Pre-Tax Income Explanation
Opus Genetics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
During the past 5 years, Opus Genetics's highest Pretax Margin was 45.68%. The lowest was -9625.30%. And the median was -52.36%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Opus Genetics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IRD has been successfully added to your 